Biopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations.
Emily O’Conno
Advertisement
Articles by Emily O’Conno
Advertisement
Latest Updated Articles
- Challenges to the Specialty Business Model
Published: June 17th 2014 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Brent Saunders: Eyeing New Horizons
2
TrumpRX Has a Blind Spot and It Can Redefine Patient Access
3
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial
4
The Cost of Fixing Pharma
5
